natgillin/translations-raw huggingface dataset:
A clinical trial in a single intensive care unit treating hyperglycaemia (blood glucose above 10 mmol/l) in 204 diabetic and 1344 non-diabetic patients undergoing major surgery showed that normoglycaemia (blood glucose 4.4 – 6.1 mmol/l) induced by intravenous Actrapid reduced mortality by 42% (8% versus 4.6%).
Klinično preskušanje zdravljenja hiperglikemije (koncentracija glukoze v krvi nad 10 mmol/l) v eni sami intenzivni enoti pri 204 bolnikih s sladkorno boleznijo in 1.344 bolnikih brez sladkorne bolezni po večji operaciji je pokazala, da je normoglikemija (koncentracija glukoze v krvi 4,4–6,1 mmol/l), dosežena z intravensko aplikacijo zdravila Actrapid, zmanjšala umrljivost za 42 % (8 % v primerjavi s 4,6 %).
A clinical trial in approximately 15 000 patients comparing reteplase with the accelerated dose regimen of alteplase (GUSTO III) (2:1 randomisation reteplase: alteplase) did not show statistically different results for the primary endpoint of 30-day mortality (reteplase: 7.47 %, alteplase 7.23 %, p = 0.61) or for the combined endpoint of 30-day mortality and non-fatal disabling stroke (reteplase: 7.89 %, alteplase 7.88 %, p = 0.99).
Klinično preskušanje pri približno 15.000 bolnikih, ki je primerjalo reteplazo s pospešenim režimom odmerjanja alteplaze (GUSTO III) (2 : 1 randomizacija reteplaza: alteplaza), ni pokazalo statistično različnih rezultatov za primarni cilj raziskave, 30-dnevno umrljivost, (reteplaza 7,47 %, alteplaza 7,23 %, p = 0,61) ali za kombinirani cilj raziskave, 30-dnevno umrljivost in onesposabljajočo kap brez smrtnega izida (reteplaza 7,89 %, alteplaza 7,88 %, p = 0,99).
A clinical trial of alogliptin as add-on therapy to pioglitazone demonstrated that there was no clinically relevant increase in hypoglycaemia rate compared to placebo.
Klinično preskušanje alogliptina kot dodatka k zdravljenju s pioglitazonom je pokazalo, da ne obstaja klinično pomembno povečanje deleža hipoglikemije v primerjavi s placebom.
A clinical trial of pioglitazone vs. gliclazide as monotherapy was extended to two years in order to assess time to treatment failure (defined as appearance of HbA1c  8.0% after the first six months of therapy).
Za oceno časa do neuspeha zdravljenja (definirano kot pojav HbA1c ≥ 8,0% po prvih šest mesecih zdravljenja) so klinično preskušanje pioglitazona v primerjavi z gliklazidom kot monoterapiji podaljšali na dve leti.
A clinically meaningful and statistically significant improvement in PFS was observed in both trials.
V obeh preskušanjih je bilo ugotovljeno klinično pomembno in statistično signifikantno podaljšanje PFS.
A clinically meaningful improvement of ≥ 1 SCBM per week, the most important secondary efficacy endpoint, was achieved in 51.0% (week 4) and 44.2% (week 12) treated with 2 mg Resolor versus 21.7% (week 4) and 22.6% (week 12) of placebo patients.
Klinično pomembno izboljšanje za ≥ 1 SCBM na teden, najpomembnejši sekundarni opazovani dogodek učinkovitosti, je bil dosežen pri 51,0 % (4. teden) in 44,2 % (12. teden) pri zdravljenju z 2 mg zdravila Resolor v primerjavi z 21,7 % (4. teden) in 22,6 % (12. teden) pri bolnikih, zdravljenih s placebom.
A clinically meaningful reduction of 50 % of biochemical markers of bone resorption was observed as early as one month after start of treatment with ibandronic acid 2.5 mg.
Klinično pomembno 50- odstotno zmanjšanje biokemičnih označevalcev kostne resorpcije so opazili že en mesec po začetku zdravljenja z 2,5 mg odmerkom ibandronske kisline.
A clinically relevant interaction with active substances with poor solubility or with narrow therapeutic index such as warfarin cannot be excluded.
Klinično pomembnega medsebojnega delovanja liraglutida in zdravilnih učinkovin s slabo topnostjo in ozkim terapevtskim indeksom, kot je na primer varfarin, ni mogoče izključiti.
A clinically relevant interaction with active substances with poor solubility or with narrow therapeutic index such as warfarin cannot be excluded.
Klinično pomembnega medsebojnega delovanja z zdravilnimi učinkovinami s slabo topnostjo in ozkim terapevtskim indeksom, kot je varfarin, ni mogoče izključiti.
A clinically relevant, low responding inhibitor was detected in 1 out of 65 BeneFIX patients (including 9 patients participating only in the surgery study) who had previously received plasma- derived products.
Klinično pomemben inhibitor, ki je zmanjšal odziv na zdravljenje, so odkrili pri 1 od 65 bolnikov (vključno z 9 bolniki, ki so sodelovali le v kirurški študiji), zdravljenih z zdravilom BeneFIX, ki so predhodno prejeli zdravila, pridobljena iz plazme.
A clinically significant interaction between sorivudine and 5-FU, resulting from the inhibition of dihydropyrimidine dehydrogenase by sorivudine, has been described.
Opisali so klinično pomembno medsebojno delovanje med sorivudinom in 5-FU, ki je rezultat sorivudinovega zaviranja dihidropirimidin dehidrogenaze.
A close latency to onset (≤ 2 weeks) following start of treatment with UMEC/VI was reported in 7/12 evaluable cases.
V 7 od 12 ocenljivih primerov so zabeležili kratko latenco (≤2 tedna) od začetka zdravljenja s kombinacijo UMEK/VI do pojava učinka.
A close temporal relationship was reported and also positive dechallenge experience which support a causal relationship between Ganfort / Ganfort PF and Eye swelling.
Poročali so o tesni časovni povezavi in tudi pozitivnem odzivu na prenehanje uporabe, kar podpira vzročno povezavo med zdravilom Ganfort/Ganfort PF in otekanjem očesa.
A coagulation test helps to identify patients with an increased bleeding risk due to increased dabigatran exposure (see sections 4.2, 4.4 and 5.1).
Pri odkrivanju bolnikov s povečanim tveganjem krvavitve zaradi povečane izpostavljenosti dabigatranu je lahko v pomoč koagulacijski test (glejte poglavja 4.2, 4.4 in 5.1).
A coagulation test helps to identify patients with an increased bleeding risk due to increased dabigatran exposure.
Test koagulacije pomaga opredeliti bolnike z večjim tveganjem za krvavitve zaradi povečane izpostavljenosti dabigatranu.
A cocktail study was conducted in 16 healthy volunteers with twice-daily 500 mg tipranavir with 200 mg ritonavir capsule administration for 10 days to assess the net effect on the activity of hepatic CYP 1A2 (caffeine), 2C9 (warfarin), 2D6 (dextromethorphan), both intestinal/hepatic CYP 3A4 (midazolam) and P-glycoprotein (P-gp) (digoxin).
Pri 16 zdravih prostovoljcih, ki so 10 dni dvakrat na dan jemali kombinacijo 500 mg tipranavirja ob 200 mg ritonavirja v obliki kapsul, so izvedli koktajl študijo, da bi ocenili neto učinek na aktivnost CYP 1A2 v jetrih (kofein), 2C9 (varfarin), 2D6 (deksametorfan), CYP 3A4 v črevesu in jetrih (midazolam) in P-glikoprotein (P-gp) (digoksin).
A cohort of 38 acromegalic subjects has been followed in a long-term, open-label, dose-titration study for at least 12 consecutive months of daily dosing with pegvisomant (mean = 55 weeks).
Kohorto 38 preiskovancev z akromegalijo so spremljali v dolgoročni, odprti študiji s titriranjem odmerka vsaj 12 zaporednih mesecev vsakodnevne uporabe pegvisomanta (povprečje = 55 tednov).
A cohort of 763 patients within Studies I and II met this criterion; the primary efficacy outcome is presented in Table 3.
Kohorta 763 bolnikov v študijah I in II je ta kriterije izpolnjevala in primarni izidi učinkovitosti so predstavljeni v preglednici 3.
a cold or the flu
prehlad ali gripa,
A collapse (floppiness) or shock-like state within 48 hours of vaccination
kolaps (ohlapnost) ali šoku podobno stanje v 48 urah po cepljenju,
A collapse or shock-like state within 48 hours of vaccination
kolaps ali šoku podobno stanje v 48 urah po cepljenju,
a collapse or ‘shock-like’ state within 48 hours of vaccination
kolaps ali »šoku podobno« stanje v 48 urah po cepljenju;
a collapse or “shock-like” state within 48 hours of vaccination
kolaps ali »šoku podobno« stanje v 48 urah po cepljenju;
A colonoscopy should also be performed in children under 12 years of age if blood is detected in their stool.
Kolonoskopijo je treba opraviti tudi pri otrocih,
A colourless to pale yellow solution.
Brezbarvna do bledo rumena raztopina.
A combination of ABILIFY solution for injection with medicines taken for anxiety might make you feel drowsy or dizzy.
Raztopina za injiciranje ABILIFY skupaj z zdravili za zdravljenje anksioznosti (tesnobe) lahko povzroči zaspanost ali omotičnost.
a combination of any of these symptoms: excessive sleepiness, dizziness, confusion, disorientation, difficulty talking, difficulty walking, muscle stiffness or shaking, fever, weakness, irritability, aggression, anxiety, increase in blood pressure, or seizures that can lead to unconsciousness.
kombinacijo katerih koli od naslednjih simptomov: pretirana zaspanost, omotica, zmedenost, dezorientacija, težave pri govoru, težave pri hoji, okorelost mišic ali tresenje, povišana telesna temperatura, šibkost, razdražljivost, agresija, anksioznost, povečan krvni tlak ali krči, ki lahko vodijo v nezavest;
A combination of immunosuppressives such as antilymphocytic antibodies (e.g. basiliximab, daclizumab) given concomitantly increases the risk of EBV- associated lymphoproliferative disorders.
Pri kombiniranem zdravljenju z imunosupresivi, npr. sočasna uporaba antilimfocitnih protiteles (npr. baziliksimab, daclizumab), se tveganje za pojav z EBV povezanih limfoproliferativnih bolezni poveča.
A combination of multiple immunosuppressants, given concomitantly increases the risk of disorders of the lymph system due to a viral infection (Epstein-Barr virus (EBV)-associated lymphoproliferative disorders).
Kombinacija več imunosupresivnih zdravil, ki se dajejo sočasno, poveča tveganje za bolezni limfnega sistema zaradi virusne okužbe (limfoproliferativne bolezni, povezane z virusom Epstein-Barr (EBV)).
A combination of roflumilast with these active substances might lead to an increase of exposure and persistent intolerability.
Pri sočasnem zdravljenju z roflumilastom in s temi učinkovinami se izpostavljenost zdravilu lahko poveča in povzroči trajno intoleranco.
A combination with ACE inhibitors or NSAIDs, for example, presents a lesser risk provided that precautions for use are strictly followed.
Na primer kombinacija z zaviralci ACE ali nesteroidnimi protivnetnimi zdravili je manj tvegana , če natančno upoštevamo previdnostne ukrepe za uporabo.
A combined efficacy and safety composite (CV death, MI, stroke, or PLATO-defined ‘Total Major’ bleeding) indicates that the benefit in efficacy of Possia compared to clopidogrel is not offset by the major bleeding events (ARR 1.4%, RRR 8%, HR 0.92; p=0.0257) over 12 months after ACS.
Kombinirana sestavljena točka učinkovitosti in varnosti (KV smrt, MI, možganska kap ali "vse hude" krvavitve po opredelitvi PLATO) kaže, da koristi glede učinkovitosti zdravila Possia v primerjavi s klopidogrelom ne odpravijo hudi krvavitveni dogodki (ARR 1,4 %, RRR 8 %, razmerje ogroženosti 0,92, p = 0,0257) v 12 mesecih po akutnem koronarnem sindromu.
A combined efficacy and safety composite (CV death, MI, stroke, or PLATO-defined ‘Total Major’ bleeding) indicates that the benefit in efficacy of ticagrelor compared to clopidogrel is not offset by the major bleeding events (ARR 1.4%, RRR 8%, HR 0.92; p=0.0257) over 12 months after ACS.
Kombiniran sestavljeni opazovani dogodek učinkovitosti in varnosti (kardiovaskularna smrt, miokardni infarkt, možganska kap ali "vse hude" krvavitve po opredelitvi PLATO) kaže, da koristi glede učinkovitosti ticagrelorja v primerjavi s klopidogrelom ne odpravijo hudi krvavitveni dogodki (ARR 1,4 %, RRR 8 %, razmerje ogroženosti 0,92, p = 0,0257) v 12 mesecih po akutnem koronarnem sindromu.
a Common = Reported in  1 patient receiving KANUMA
a Pogosti = o njih so poročali pri  1 bolniku, ki je dobival zdravilo KANUMA
A common maintenance dose is 20 – 30 mg per day, given once daily in the morning.
Običajni vzdrževalni odmerek je 20–30 mg na dan, ki se daje enkrat na dan, in sicer zjutraj.
A common side effect (these may affect up to 1 in 10 people) is:
Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov):
A common side effect is ‘circulatory overload’ (when the blood fluid leaks out of the blood vessels), which causes tachypnea (rapid breathing), dyspnea (shortness of breath), harsh lung sounds and pulmonary oedema (fluid accumulation in the lungs).
Pogost neželen učinek je „preobremenitev krvnega obtoka“ (kadar tekoči del krvi pronica iz žil), kar povzroči tahipnejo (hitro dihanje), dispnejo (zasopljenost), rezke glasove v pljučih in pljučni edem (zbiranje tekočine v pljučih).
A common side effect which may show up in blood tests is: an increase in the level of an enzyme produced in the muscles (creatine phosphokinase) which may be a sign that body tissue is damaged.
Pogost neželeni učinek, ki se lahko pokaže pri preiskavah krvi, je: zvišana vrednost encima, ki nastaja v mišicah (kreatin-fosfokinaze); to je lahko znak okvare telesnega tkiva.
A common side effect which may show up in blood tests is: an increase in the level of an enzyme produced in the muscles(creatine phosphokinase) which may be a sign that body tissue is damaged.
Pogost neželeni učinek, ki se lahko pokaže pri preiskavah krvi, je: zvišana vrednost encima, ki nastaja v mišicah (kreatin-fosfokinaze); to je lahko znak okvare telesnega tkiva.
A commonly used regimen for superovulation involves the administration of 150-225 IU of follitropin alfa daily commencing on days 2 or 3 of the cycle.
Režim, ki se običajno uporablja za superovulacijo, vključuje dajanje 150–225 i.e. folitropina alfa na dan, s pričetkom na 2. ali 3. dan ciklusa.
A comparable proportion of patients in both groups developed anti-asparaginase antibodies before the start of the post-induction treatment phase (Spectrila 54.6 % vs. reference E. coli-asparaginase
V obeh skupinah so se pri primerljivem deležu bolnikov razvila antiasparaginazna protitelesa pred začetkom faze postindukcijskega zdravljenja (zdravilo Spectrila 54,6 % proti referenčni asparaginazi
A comparative study between lapatinib and trastuzumab in this patient population has not been conducted.
Primerjalna študija lapatiniba in trastuzumaba v tej populaciji bolnic ni bila izvedena.
A comparative study between the freezedried and the liquid formulation showed bioequivalence between the two formulations.
Primerjalna študija zmrzovalno sušene oblike zdravila in tekoče oblike je pokazala bioekvivalenco obeh oblik zdravila.
A comparative study in 1279 subjects who received M-M-RVAXPRO or the previous formulation (manufactured with human serum albumin) of the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc. demonstrated similar immunogenicity and safety between the 2 products.
Primerjalna študija s 1279 osebami, ki so bile cepljene s cepivom M-M-RVAXPRO ali prejšnjo obliko cepiva (izdelano s humanim serumskim albuminom) proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc., je pokazala, da sta imunogenost in varnost teh 2 cepiv podobni.
a Compared with INV CHOICE based on Cox proportional hazard model. b Disease assessment is based on radiographic review by independent radiologists and review of clinical data by independent oncologists. c Compared with INV CHOICE based on log-rank test. d Compared with INV CHOICE alone based on Fisher's exact test.
a V primerjavi z INV CHOICE (= zdravljenje po izbiri raziskovalca) na podlagi Coxovega modela proporcionalnega tveganja. b Ocena bolezni temelji na radiografskem pregledu neodvisnih radiologov in pregledu kliničnih podatkov s strani neodvisnih onkologov. c V primerjavi z INV CHOICE na podlagi testa log-rank. d V primerjavi z INV CHOICE samo na podlagi Fisherjevega eksaktnega testa.
a Comparison based on historic control.
a Primerjava temelji na zgodovinski kontroli
A comparison of a regimen including once daily versus twice daily dosing of abacavir and lamivudine was undertaken within a randomised, multicentre, controlled study of HIV-infected, paediatric patients.
V okviru randomizirane, multicentrične, kontrolirane študije z virusom HIV okuženih pediatričnih bolnikov, so primerjali režima odmerjanja abakavirja in lamivudina enkrat v primerjavi z dvakrat na dan.
A comparison of post-treatment ALT elevations between weeks 52 and 68 in patients who discontinued lamivudine at week 52 and patients in the same studies who received placebo throughout the treatment course is shown in Table 2.
V preglednici 2 je prikazano povišanje vrednosti ALT po zdravljenju med 52. in 68. tednom pri bolnikih, ki so jim v 52. tednu ukinili lamivudin, v primerjavi z bolniki v isti študiji, ki so celotno obdobje zdravljenja dobivali placebo.
A comparison of progression shall be made to the expected untreated progression rate.
Narejena bo primerjava s pričakovano hitrostjo napredovanja brez zdravljenja.
A comparison of the paediatric and adult population pharmacokinetic data indicated that the predicted total exposure (AUCτ ) in children following administration of a 9 mg/kg IV loading dose was comparable to that in adults following a 6 mg/kg IV loading dose.
Primerjava podatkov populacijske farmakokinetike pediatrične in odrasle populacije kaže, da je bila pričakovana celokupna izpostavljenost (AUC) pri otrocih po uporabi 9 mg/kg intravenskega polnilnega odmerka primerljiva s tisto pri odraslih po uporabi 6 mg/kg intravenskega polnilnega odmerka.
A comparison of XELOX plus bevacizumab versus FOLFOX-4 plus bevacizumab was a pre- specified exploratory analysis.
Primerjava zdravljenja po shemi XELOX v kombinaciji z bevacizumabom in zdravljenja po shemi FOLFOX-4 v kombinaciji z bevacizumabom je bila vnaprej določena eksploratorna analiza.
A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until ANC > 1.5 x 109/l and platelet count > 100 x 109 /l.
Na 22. dan (21 dni po prvem odmerku) ali v roku 48 ur od navedenega dne, morate pregledati celotno krvno sliko in jo nato spremljati vsak teden, dokler ni ANC > 1,5 x 109/l in število trombocitov > 100 x 109/l.
A complete blood count, including a white blood cell count differential, must be performed before initiating therapy with Jakavi.
Pred začetkom zdravljenja z zdravilom Jakavi je treba določiti celotno krvno sliko, vključno z diferencialno belo krvno sliko.
a Complete clearance rate is defined as the proportion of patients with no (zero) clinically visible actinic
a Stopnja popolne ozdravitve je opredeljena kot delež bolnikov brez (tj. z nič) klinično vidnih lezij zaradi
a Complete clearance rate was defined as the proportion of patients with no (zero) clinically visible actinic keratosis lesions in the treatment area. b Partial clearance rate was defined as the percentage of patients in whom 75% or more of the number of baseline
a Stopnja popolne ozdravitve je bila opredeljena kot odstotek bolnikov brez (z nič) klinično vidnih lezij zaradi aktinične keratoze na zdravljenem mestu. b Stopnja delne ozdravitve je bila opredeljena kot odstotek bolnikov, pri katerih je bilo ozdravljenih vsaj 75
A concentration dependent increase in QTc was not detected.
Od koncentracije odvisnega podaljšanja QTc niso odkrili.
A concentration-dependent reduction in free PCSK9 and LDL-C is observed until target saturation is achieved.
Dokler ni dosežena zasičenost ciljnega mesta, je opazno od koncentracije odvisno znižanje prostega PCSK9 in LDL-H.
A concentration-QTc response analysis based on the data from Study A demonstrated that at average steady-state concentrations the upper bound of the 2-sided 90% CI for QTc increase from baseline was 16 msec at Zykadia 750 mg.
Rezultati analize povezanosti med koncentracijo in odzivom intervala QTc na podlagi podatkov iz študije A so pokazali, da je pri povprečni koncentraciji v stanju dinamičnega ravnovesja pri odmerjanju zdravila Zykadia v odmerku 750 mg zgornja meja dvostranskega 90-odstotnega intervala zaupanja za podaljšanje intervala QTc od izhodiščne vrednosti 16 ms.
a condition affecting the blood vessels in your brain called ‘cerebrovascular disorder’ (stroke or brain bleeding)
tanje, ki prizadene žile v možganih, imenovano cerebrovaskularna bolezen (kap ali krvavitev iz možganov),
a condition affecting the blood vessels in your brain called ‘cerebrovascular disorder’ (stroke or brain bleeding)
tanje, ki prizadene žile v možganih, imenovano »cerebrovaskularna bolezen« (kap ali krvavitev iz možganov),
a condition affecting the blood vessels in your brain called ‘cerebrovascular disorder’” (stroke or brain bleeding)
tanje, ki prizadene žile v možganih, imenovano cerebrovaskularna bolezen (kap ali krvavitev iz možganov),
a condition affecting the blood vessels in your brain called ‘“cerebrovascular disorder”’ (stroke or brain bleeding)
tanje, ki prizadene žile v možganih, imenovano cerebrovaskularna bolezen (kap ali krvavitev iz možganov),
A condition called posterior reversible encephalopathy syndrome (PRES) has been rarely reported in MS patients treated with Gilenya.
Pri bolnikih z multiplo sklerozo, ki so prejemali zdravilo Gilenya, so v redkih primerih poročali o bolezni, ki se imenuje sindrom posteriorne reverzibilne encefalopatije.
A condition called posterior reversible encephalopathy syndrome (PRES) or reversible posterior leukoencephalopathy syndrome (RPLS), which has symptoms such as seizures, headaches, confusion, or finding it difficult to concentrate
Stanje, imenovano sindrom posteriorne reverzibilne levkoencefalopatije (RPLS, Reversible Posterior Leukoencephalopathy Syndrome), znan tudi kot sindrom posteriorne reverzibilne encefalopatije (PRES, Posterior Reversible Encephalopathy Syndrome) s simptomi, kot so epileptični napadi, glavobol, zmedenost ali težave s koncentracijo
A condition called Pure Red Cell Aplasia (PRCA, stopped or reduced production of red blood cells) due to anti-erythropoietin antibodies was observed in some patients treated with erythropoiesis stimulating agents (ESAs), including MIRCERA.
Pri nekaterih bolnikih, zdravljenih z zdravili za spodbujanje eritropoeze (ESA), vključno z zdravilom MIRCERA, so opazili stanje - imenovano čista aplazija rdečih krvnih celic (prekinjeno ali zmanjšano nastajanje rdečih krvnih celic), ki nastane zaradi protiteles proti eritropoetinu.
a condition known as hyperhomocysteinaemia
motnjo, imenovano hiperhomocisteinemija;
a condition known as hyperhomocysteinaemia
tanje, znano kot hiperhomocisteinemija
a condition known as ‘acute coronary syndrome’, when it should be given with aspirin (another medicine that prevents blood clots).
imajo akutni koronarni sindrom, pri katerih se mora zdravilo dajati skupaj z aspirinom (drugim zdravilom za preprečevanje krvnih strdkov).
a condition known as ‘acute coronary syndrome’, when it should be given with aspirin (another medicine that prevents blood clots).
ki imajo akutni koronarni sindrom, pri katerem se mora zdravilo dajati skupaj z aspirinom (drugim zdravilom za preprečevanje krvnih strdkov).
a condition that could lead to reduced supply of oxygen to body tissues (such as in patients who are being treated for worsening heart failure, have recently had a heart attack, have breathing problems or a steep fall in blood pressure); liver impairment, or problems with alcoholism or alcohol intoxication.
obolenjem, ki lahko povzroči zmanjšano dovajanje kisika v tkiva (npr. pri bolnikih, ki se zdravijo zaradi srčnega popuščanja, so pred kratkim doživeli srčni napad, imajo težave z dihanjem ali nenaden padec krvnega tlaka); jetrno okvaro ali težavami z alkoholizmom ali zastrupitvijo z alkoholom.
a condition that could lead to reduced supply of oxygen to body tissues (such as in patients who are being treated for worsening heart failure, have recently had a heart attack, have difficulty breathing or a steep fall in blood pressure); liver impairment, or problems with alcoholism or alcohol intoxication.
obolenjem, ki lahko povzroči zmanjšano dovajanje kisika v tkiva (npr. pri bolnikih, ki se zdravijo zaradi srčnega popuščanja, so pred kratkim doživeli srčni napad, imajo oteženo dihanje ali nenaden padec krvnega tlaka); jetrno okvaro ali težavami z alkoholizmom ali zastrupitvijo z alkoholom.
a condition where there is too much acid in the body
tanje s preveč kisline v telesu
a condom (with spermicide, if available) a diaphragm (with spermicide, if available).
kondom (s spermicidom, če je mogoče), diafragma (s spermicidom, če je mogoče).